Human immune deficiency virus (HIV) infection is frequently reported in Egypt. This study introduces a new approach for HIV eradication based on a new enzyme combination reverse transcriptase and DNA polymerase (VK 25 RD) formula for inhibiting and or preventing the disease. This pilot study was done on five naive patients who were all positive for HIV antibodies, never treated with anti retroviral medications. Those patients were registered and under surveillance by Human immune deficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) Control Department at the Egyptian Ministry of Health (MOH). Their immunological data revealed a viral load of more than 1,000 copies/ml by human immune deficiency virus-ribonucleic acid-polymerase chain reaction (HIV-RNA-PCR), and antibody positive to HIV-1 and CD4+ T-cell values less than 250 cells/μl. All of the patients showed the same clinical symptoms of HIV/AIDS and wrote consent of acceptance to take this combination therapy in the form of subcutaneous injection of 0.1 cc twice daily for 24 weeks. At the end of therapy, all of the patient's viral loads had reached under the detectable limits (less than 16 copies/ml); also there were significant increases of their CD4 cells count over 500 cells/μl. According to these findings, this therapeutic modality was promising for treating HIV-1 disease and human immunodeficiency syndrome.
Key words: (VK 25 RD) Reverse transcriptase (RT), DNA polymerase mixture formula, acquired immune deficiency syndrome (AIDS), Human immune deficiency virus (HIV).
Copyright © 2021 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0